fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2010-05-12 Ergonex Pharma (Switzerland)
Pfizer (USA)
terguride (oral antagonist of 5-HT2B and 5-HT2A (serotonin) receptors) / pulmonary arterial hypertension commercialization/ distribution
other
See details
2010-05-11 Addex (Switzerland)
Ortho-McNeil-Janssen Pharmaceuticals/J&J (USA)
ADX71149 (mGluR2 positive allosteric modulator-PAM) / anxiety, depression, schizophrenia and Alzheimer's disease R&D
commercialization/ distribution
development
See details
2010-05-11 Swedish Orphan Biovitrum (Sweden)
Biomodels (USA)
assay for mucositis risk in cancer treatment
/ mucositis risk in cancer treatment
R&D
See details
2010-05-10 Evotec (Germany)
Genentech (USA)
novel small molecule therapeutics R&D
other
See details
2010-05-10 bioMérieux (France)
GSK (UK)
companion test / metastatic melanoma R&D
other
See details
2010-05-10 Intercell (Austria)

Boehringer Ingelheim Vetmedica (Germany)
antigens derived from Intercell’s Antigen Identification Program (AIP®) to develop animal vaccines
Intercell's AIP® has already been used to identify relevant and protective antigens for several bacterial pathogens including Staphylococcus aureus and epidermidis, Streptococcus pneumoniae, Streptococcus agalactiae and pyogenes, Enterococcus faecalis, Klebsiella pneumoniae, Borrelia spp., ETEC, Shigella, Campylobacter jejuni, non-typable Haemophilus influenzae, and Moraxella catarrhalis.
/ undisclosed animal diseases
R&D
licensing
See details
2010-05-07 SynCo Bio Partners (the Netherlands)
OncoMed Pharmaceuticals (USA)
antibodies manufacturing
See details
2010-05-07 Glenmark (India)
Sanofi-Aventis (France)
vanilloid receptor (TRPV3) antagonist molecules, including a first-in-class clinical compound, GRC 15300.

The TRPV3 receptor is an ion channel protein that mediates and influences cell signaling, including the nerve cell signaling that generates some types of pain. Inhibitors of TRPV3 are predicted to be useful in the treatment of inflammation, various pain conditions, and other diseases and disorders. / chronic pain
R&D
licensing
commercialization/ distribution
marketing/ promotion
See details
2010-05-06 Intercell (Austria)
Cytos Biotechnology (Switzerland)
platform technology for monoclonal antibody discovery / infectious diseases with a focus on group B Streptococcus and bacteria involved in hospital acquired infections other
See details
2010-05-05 Micromet (Germany-USA)
Boehringer Ingelheim (Germany)
BiTE® antibody / multiple myeloma R&D
licensing
manufacturing
commercialization/ distribution
development
marketing/ promotion
See details
2010-05-05 EndoCeutics (Canada)
Bayer Schering Pharma (Germany)
Vaginorm® (intra-vaginal application of dehydroepiandrosterone-DHEA) / vulvovaginal atrophy and female sexual dysfunction in postmenopausal women licensing
manufacturing
commercialization/ distribution
development
marketing/ promotion
See details
2010-05-04 Vernalis (UK)
Servier (France)
/ cancer R&D
See details
2010-05-04 Stemgent (USA)
Miltenyi Biotec (Germany)
stem cell research products commercialization/ distribution
development
other
See details
2010-05-03 Targacept (USA)

AstraZeneca (UK)
TC-5619 (small molecule highly selective for the alpha7 NNR) / attention deficit/hyperactivity disorder (ADHD)
Alzheimer's disease
cognitive dysfunction in schizophrenia
licensing
commercialization/ distribution
development
See details
2010-05-03 Epigenomics (Germany)
Warnex Medical Laboratories (Canada)
Septin9 biomarker for colorectal cancer blood test screening / colorectal cancer licensing
See details
[<<]      «      1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [65]